Research programme: Epstein-Barr virus immunotherapy - Genocea Biosciences

Drug Profile

Research programme: Epstein-Barr virus immunotherapy - Genocea Biosciences

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genocea Biosciences
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epstein-Barr virus infections

Most Recent Events

  • 10 Aug 2017 Preclinical trials in Epstein-Barr virus infections in USA (unspecified route)
  • 05 Nov 2015 Early research in Epstein-Barr virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top